CA-BITMOVIN
2.9.2020 02:21:05 CEST | Business Wire | Press release
Bitmovin, a leading provider of video infrastructure for digital media companies around the world, today announced Bitmovin Live – IBC Edition, its latest, live virtual event series with tech sessions that will be of interest to streaming/OTT and technology industry executives, in addition to developers across the globe. The focus for this series of events is innovative ways to reduce the costs of video distribution and app development and optimizing video workflows to elevate the viewer experience. Bitmovin Live – IBC Edition will take place from September 8th – 24th. All sessions will be available on-demand for those not able to view the events live. More information on Bitmovin Live – IBC Edition, and to register, visit: https://www.bitmovin.com/ibc-edition
“The Bitmovin Live series has demonstrated how it has been possible to adapt quickly and effectively to an online-only conference format in response to COVID-19,” said Ben Dales, Digital Media Manager from the broadcast and media technology industry trade group IABM. “IABM has long been a champion of collaboration, and with Bitmovin Live - IBC Edition, we are impressed to see Bitmovin expand its involvement to partners, industry leaders, and sometimes even competitors in the spirit of providing a place for the community to thrive despite the global challenges.”
The marquee event kicks-off on September 10th with executives from Roku, YouTube, Sky Studios, ViacomCBS and Bitmovin discussing “Succeeding in the Global Streaming Economy.” Variety International Editor Manori Ravindran will moderate the conversation that will be hosted in the “Variety Streaming Room ” presented by Bitmovin on Sept. 10 at 9 a.m. PT/12 p.m. ET. To sign up, please visit: Variety Streaming Room: Succeeding in the Global Streaming Economy
The closing session, moderated by IABM on September 23rd, will be “Innovating SVOD and AVOD strategies for reshaped media landscape.” Sign up at Innovating AVOD and SVOD strategies
Bitmovin is dedicated to using new and innovative ways of interacting with event participants. As a compliment to the usual programming of webinars, tech talks and panels, it has created a “Virtual VR Event Booth,” a space that can bring prospects and customers closer to Bitmovin’s employees and services.
“The ‘Virtual VR Event Booth’ will showcase a high-level overview of Bitmovin origins, the value the company brings, as well as a look at the solutions and products that are offered,” said Jamie Attfield, Head of Design at Bitmovin. “Attendees are also free to explore an assortment of collateral pieces that can be downloaded to their machines and devices for further reading. This experience will be accessible on mobile, desktop and Oculus Quest, bringing a new perspective on how the company can communicate in the digital realm.”
About Bitmovin:
Built for technical professionals in the OTT video market, Bitmovin’s software solutions help you optimize customer operations and reduce time-to-market, resulting in the best viewer experience imaginable. This is achieved through our device reach, flexible and scalable integration, and commitment to supporting our customers. Learn more at www.bitmovin.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200901006133/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom